HIV molecular immunology database


Search Antibody Database

Found 1 matching record:

Displaying record number 454

Download this epitope record as JSON.

MAb ID CGP 47 439 (CGP 47,439)
HXB2 Location gp160(304-322)
gp160 Epitope Map
Author Location gp120
Epitope RKRIRIQRGPGRAFVTIGK? Epitope Alignment
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L
Species (Isotype) human, mouse
Immunogen vaccine
Keywords antibody generation, immunotherapy, neutralization, review

Vaccine Details

Vaccine type protein
Vaccine strain B clade IIIB
Vaccine component gp120


Showing 6 of 6 notes.


Showing 6 of 6 references.

Isolation Paper
Liou1989 R. S. Liou, E. M. Rosen, M. S. C. Fung, W. N. C. Sun, C. Sun, W. Gordon, N. T. Chang, and T. W. Chang. A Chimeric Mouse-Human Antibody That Retains Specificity for HIV-1 gp120 and Mediates the Lysis of the HIV-1-Infected Cells. J. Immunol., 143:3967-3975, 1989. PubMed ID: 2480382. Show all entries for this paper.

Chen2009b Weizao Chen and Dimiter S. Dimitrov. Human Monoclonal Antibodies and Engineered Antibody Domains as HIV-1 Entry Inhibitors. Curr. Opin. HIV AIDS, 4(2):112-117, Mar 2009. PubMed ID: 19339949. Show all entries for this paper.

Gauduin1998 M. C. Gauduin, R. Weir, M. S. Fung, and R. A. Koup. Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses, 14:205-11, 1998. Post-exposure passive transfer of murine BAT123 can confer protection to hu-PBL-SCID mice challenged with HIV-1 LAI, and the mechanism is by complement-mediated cytolysis or virolysis. This protection was not conferred by CGP 47 439, a BAT123 chimera that has a human IgG$_1$ Fc domain, substituted in place of a murine IgG$_1$ Fc domain, suggesting that the protection is mediated by complement. Further evidence was that the protective ability of BAT123 is lost when mice were treated with cobra venom factor, which inactivates serum complement. IgG$_1$ does not fix complement efficiently, so an IgG$_2$ MAb might perform better. Therefore, in spite of the potential for enhancement in some circumstances, in this circumstance complement activation provided a protective advantage. PubMed ID: 9491910. Show all entries for this paper.

Gunthard1994 H. F. Gunthard, P. L. Gowland, J. Schupbach, M. S. C. Fung, J. Boni, R.-S. Liou, N. T. Chang, P. Grob, P. Graepel, D. G. Braun, and R. Luthy. A Phase I/IIA Clinical Study with a Chimeric Mouse-Human Monoclonal Antibody to the V3 Loop of Human Immunodeficiency Virus Type I gp120. J. Infect. Dis., 170:1384-1393, 1994. PubMed ID: 7995976. Show all entries for this paper.

Jacobson1998 J. M. Jacobson. Passive Immunization for the Treatment of HIV Infection. Mt. Sinai J. Med., 65:22-26, 1998. Review. PubMed ID: 9458680. Show all entries for this paper.

Safrit1993 J. T. Safrit, M. S. C. Fung, C. A. Andrews, D. G. Braun, W. N. C. Sun, T. W. Chang, and R. A. Koup. hu-PBL-SCID Mice Can Be Protected from HIV-1 Infection by Passive Transfer of Monoclonal Antibody to the Principal Neutralizing Determinant of Envelope gp120. AIDS, 7:15-21, 1993. PubMed ID: 7680205. Show all entries for this paper.

Questions or comments? Contact us at
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health